Evacetrapib (LY2484595) Clinical Trials

Size	Price	Qty
5mg	USD 210

Clinical Trials

Sponsored by Eli Lilly and Company, numerous clinical trials spanning Phase 1, Phase 2, and Phase 3 have evaluated evacetrapib across conditions including dyslipidemia, hypercholesterolemia, hyperlipidemia, hepatic insufficiency, and cardiovascular disease, alongside pharmacokinetic and bioequivalence evaluations. While several studies assessing bioequivalence and pharmacokinetics have been completed, other trials within the program were terminated. Together, these evaluations characterize the compound's pharmacokinetic behavior, drug interaction potential, and therapeutic profile in populations affected by metabolic and cardiovascular conditions.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01687998	TERMINATED	Cardiovascular Diseases	Eli Lilly and Company	2012-10	PHASE3
NCT02227784	TERMINATED	Hyperlipidemia	Eli Lilly and Company	2014-10	PHASE3
NCT02168803	COMPLETED	Dyslipidemia	Eli Lilly and Company	2014-05	PHASE1
NCT02497391	COMPLETED	Healthy	Eli Lilly and Company	2015-07	PHASE1
NCT02260648	TERMINATED	Hypercholesterolemia	Eli Lilly and Company	2015-01	PHASE3
NCT02497391	Completed	Healthy	Eli Lilly and Company	2015-07	Phase 1
NCT02260635	TERMINATED	Hypercholesterolemia	Eli Lilly and Company	2014-11	PHASE3
NCT02226653	COMPLETED	Healthy Volunteers	Eli Lilly and Company	2014-09	PHASE1
NCT02365558	COMPLETED	Healthy	Eli Lilly and Company	2015-01	PHASE1
NCT02365558	Completed	Healthy	Eli Lilly and Company	2015-01	Phase 1
NCT02156492	COMPLETED	Healthy Volunteers	Eli Lilly and Company	2014-06	PHASE1
NCT02271425	COMPLETED	Healthy Volunteers	Eli Lilly and Company	2014-10	PHASE1
NCT02271425	Completed	Healthy Volunteers	Eli Lilly and Company	2014-10	Phase 1
NCT02226653	Completed	Healthy Volunteers	Eli Lilly and Company	2014-09	Phase 1
NCT02161731	COMPLETED	Healthy Volunteers	Eli Lilly and Company	2014-06	PHASE1
NCT02156492	Completed	Healthy Volunteers	Eli Lilly and Company	2014-06	Phase 1
NCT02168803	Completed	Dyslipidemia	Eli Lilly and Company	2014-05	Phase 1
NCT01958489	COMPLETED	Healthy Volunteers	Eli Lilly and Company	2013-10	PHASE1
NCT01903434	COMPLETED	Healthy Volunteers	Eli Lilly and Company	2013-07	PHASE1
NCT01836185	COMPLETED	Hepatic Insufficiency	Eli Lilly and Company	2013-04	PHASE1
NCT01825889	COMPLETED	Cardiovascular Disease	Eli Lilly and Company	2013-04	PHASE1
NCT01908582	COMPLETED	Healthy Volunteers	Eli Lilly and Company	2013-07	PHASE1
NCT01897493	COMPLETED	Healthy Volunteers	Eli Lilly and Company	2013-07	PHASE1
NCT01810432	COMPLETED	Healthy Volunteers	Eli Lilly and Company	2013-03	PHASE1
NCT01825876	COMPLETED	Healthy Volunteers	Eli Lilly and Company	2013-04	PHASE1
NCT01746732	COMPLETED	Healthy Volunteers	Eli Lilly and Company	2012-12	PHASE1
NCT01736254	COMPLETED	Healthy Volunteers	Eli Lilly and Company	2012-12	PHASE1
NCT01537887	COMPLETED	Healthy Volunteers	Eli Lilly and Company	2012-02	PHASE1
NCT01375075	COMPLETED	Dyslipidemias	Eli Lilly and Company	2011-06	PHASE2
NCT01448824	COMPLETED	Healthy Participants	Eli Lilly and Company	2011-10	PHASE1
NCT01450098	COMPLETED	Healthy Volunteers	Eli Lilly and Company	2011-10	PHASE1
NCT01105975	COMPLETED	Dyslipidemia	Eli Lilly and Company	2010-04	PHASE2

(data from https://clinicaltrials.gov, updated on 2019-10-08)

Check the Evacetrapib (LY2484595) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Evacetrapib selectively binds to and inhibits cholesteryl ester transfer protein (CETP) with an IC50 of 5.5 nM, thereby blocking the neutral lipid transfer of cholesteryl esters from high-density lipoproteins to pro-atherogenic low-density lipoproteins. By elevating circulating high-density lipoprotein cholesterol levels without triggering aldosterone release or raising blood pressure, this target inhibition offers a mechanistic basis for managing dyslipidemia, hypercholesterolemia, and cardiovascular disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).